Strides Pharma Science
Strides Pharma Science Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Strides Pharma Science
Start SIPStrides Pharma Science Investment Rating
-
Master Rating:
-
Strides Pharma Science has an operating revenue of Rs. 3,688.39 Cr. on a trailing 12-month basis. An annual revenue growth of 18% is outstanding, Pre-tax margin of 0% needs improvement, ROE of -9% is poor and needs improvement. The company has a debt to equity of 52%, which is bit higher. The stock from a technical standpoint is comfortably placed above its key moving averages, around 7% and 9% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 8% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 18 which is a POOR score indicating inconsistency in earnings, a RS Rating of 62 which is FAIR indicating the recent price performance, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 95 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 564 | 387 | 481 | 423 | 456 |
| Operating Expenses Qtr Cr | 444 | 341 | 487 | 484 | 438 |
| Operating Profit Qtr Cr | 119 | 46 | -6 | -61 | 18 |
| Depreciation Qtr Cr | 23 | 22 | 24 | 24 | 24 |
| Interest Qtr Cr | 43 | 35 | 35 | 26 | 22 |
| Tax Qtr Cr | 3 | 5 | -40 | -38 | -144 |
| Net Profit Qtr Cr | 62 | 13 | -4 | -66 | 201 |
Strides Pharma Science Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 8
- Bearish Moving Average
- ___
- 8
- 20 Day
- ₹359.41
- 50 Day
- ₹343.15
- 100 Day
- ₹332.71
- 200 Day
- ₹338.23
- 20 Day
- ₹364.87
- 50 Day
- ₹334.62
- 100 Day
- ₹320.08
- 200 Day
- ₹327.19
Strides Pharma Science Resistance and Support
| Resistance | |
|---|---|
| First Resistance | ₹363.17 |
| Second Resistance | ₹366.84 |
| Third Resistance | ₹371.82 |
| RSI | 51.59 |
| MFI | 41.31 |
| MACD Single Line | 9.41 |
| MACD | 6.07 |
| Support | |
|---|---|
| First Resistance | ₹354.52 |
| Second Resistance | ₹349.54 |
| Third Resistance | ₹345.87 |
Strides Pharma Science Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 166,480 | 8,072,615 | 48.49 |
| Week | 343,030 | 17,178,932 | 50.08 |
| 1 Month | 718,817 | 29,478,693 | 41.01 |
| 6 Month | 475,187 | 18,361,212 | 38.64 |
Strides Pharma Science Result Highlights
Strides Pharma Science Synopsis
NSE-Medical-Generic Drugs
Strides Pharma Scien is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1854.50 Cr. and Equity Capital is Rs. 90.30 Cr. for the Year ended 31/03/2023. Strides Pharma Science Ltd. is a Public Limited Listed company incorporated on 28/06/1990 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24230MH1990PLC057062 and registration number is 057062.| Market Cap | 3,232 |
| Sales | 1,854 |
| Shares in Float | 6.50 |
| No of funds | 114 |
| Yield | 0.36 |
| Book Value | 0.93 |
| U/D Vol ratio | 1.7 |
| LTDebt / Equity | 8 |
| Alpha | 0.01 |
| Beta | 1.08 |
Strides Pharma Science
| Owner Name | Mar-23 | Dec-22 | Sep-22 | Jun-22 |
|---|---|---|---|---|
| Promoters | 28.27% | 30.89% | 31.07% | 30.37% |
| Mutual Funds | 11.14% | 11.65% | 8.32% | 9.81% |
| Insurance Companies | 5.2% | 5.26% | 5.26% | |
| Foreign Portfolio Investors | 18.85% | 18.98% | 21.43% | 21.21% |
| Financial Institutions/ Banks | 0.01% | 0.01% | 0.01% | 0.01% |
| Individual Investors | 25.51% | 22.43% | 22.4% | 22.29% |
| Others | 11.02% | 10.78% | 11.51% | 16.31% |
Strides Pharma Science Management
| Name | Designation |
|---|---|
| Mr. Arun Kumar | Exe.Chairman & Mng.Director |
| Mr. Badree Komandur | Executive Director & Group CFO |
| Mr. Deepak Vaidya | Non Executive Director |
| Dr. Kausalya Santhanam | Independent Director |
| Mr. Bharat D Shah | Independent Director |
| Mr. Homi Rustam Khusrokhan | Independent Director |
| Mr. S Sridhar | Independent Director |
Strides Pharma Science Forecast
Price Estimates
Strides Pharma Science Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2023-05-25 | Audited Results & Final Dividend | |
| 2023-01-24 | Quarterly Results | |
| 2022-11-14 | Quarterly Results | |
| 2022-07-29 | Quarterly Results | |
| 2022-07-25 | Others | Inter alia, to consider and approve Intimation of raising of funds by way of issuance of Non-Convertible Debentures under Regulation 29 of SEBI Listing Regulations. per share(20%)Final Dividend |
| Date | Purpose | Remarks |
|---|---|---|
| 2021-08-06 | FINAL | Rs.2.50 per share(25%)Final Dividend |
Strides Pharma Science FAQs
What is Share Price of Strides Pharma Science ?
Strides Pharma Science share price is ₹357 As on 06 June, 2023 | 00:15
What is the Market Cap of Strides Pharma Science ?
The Market Cap of Strides Pharma Science is ₹3232.4 Cr As on 06 June, 2023 | 00:15
What is the P/E ratio of Strides Pharma Science ?
The P/E ratio of Strides Pharma Science is -16 As on 06 June, 2023 | 00:15
What is the PB ratio of Strides Pharma Science ?
The PB ratio of Strides Pharma Science is 1.5 As on 06 June, 2023 | 00:15